−4.5386USD
−12.54 MUSD
4.02 M
About Salarius Pharmaceuticals, Inc.
Sector
Industry
CEO
David J. Arthur
Website
Headquarters
Houston
Employees (FY)
2
Founded
2014
ISIN
US79400X3052
FIGI
BBG00740LLD5
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
$SLRX Target PTs 2.50-3.50Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and
Stock Play: SLRXWhite lines are resistance, purple are support - Play the targets how you please... a close above 1.92 and we’ll get our trek to 5!! Accumulate while you can. Volume has been beautiful the last couple months. Looks like a solid setup, but know your risk.
$SLRX can rise in the next daysContextual immersion trading strategy idea.
Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments.
The demand for shares of the company looks higher than the supply.
This and other conditions can cause a rise in the share price in the n
SLRX - Sky's the limit (550% potential upside)SLRX has formed a perfect bottoming pattern on the weekly chart.
Technical reasons for the trade:
→ Double bottom (and another smaller double bottom recently!)
→ Highest weekly volume ever
→ Break above the POC
→ Price still trading within the reload zone (0.618 fib)
→ Weekly price gaps above ma
The SLRX slide and its is not PDUFAWhat did I missed that caused the SLRX to slid? Was there an indicator that I should've taken as an exit plan? or is there some indications that I should have taken into consideration as one of my entry criteria? Did I also missed any information I missed prior taking a position?
Recap of catal
4 Penny Stocks I'm Bullish On: MARK, BBI, ADOM, and SLRXThese are currently 4 penny stocks that I'm bullish on for a potential reentry: $MARK been beaten up alot, and I think the resistance might pop soon for a gap fill. BBI has been mostly bearish and should retrace soon for the next positive wedge. ADOM is a long hold. SLRX is one of those stocks that
SLRX is moving high, but why?(NOTE: Use daily chart then move to weekly to see my thesis)
NASDAQ:SLRX
There is a strong sense of optimism for SLRX because of the PDUFA for Seclidemstat in P 1/2 Ewing Sarcoma trial this June 17, 2020. Most small bios like SLRX are typically driven by these types of updates, but it comes with
SLRX Overbought Hello,
What is SLRX?
Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, b
SLRX Peaked at $1.70 Today than Down, Possible Retracement?First off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, SLRX have pulled a bullish run and then crash within an hour. This was likely due to some automated trigger by some large fund starting to slowly upward increm
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SLRX is 0.4848 USD — it has decreased by 5.04% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Salarius Pharmaceuticals, Inc. stocks are traded under the ticker SLRX.
Salarius Pharmaceuticals, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
SLRX stock is 5.82% volatile and has beta coefficient of −0.64. Check out the list of the most volatile stocks — is Salarius Pharmaceuticals, Inc. there?
One year price forecast for Salarius Pharmaceuticals, Inc. has a max estimate of 3.2500 USD and a min estimate of 3.2500 USD.
SLRX earnings for the last quarter are −1.43 USD per share, whereas the estimation was −1.30 USD resulting in a −10.28% surprise. The estimated earnings for the next quarter are −0.67 USD per share. See more details about Salarius Pharmaceuticals, Inc. earnings.
Salarius Pharmaceuticals, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 1.16 M USD. In the next quarter revenue is expected to reach 325.00 K USD.
Yes, you can track Salarius Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
SLRX stock has fallen by 3.04% compared to the previous week, the month change is a 17.83% fall, over the last year Salarius Pharmaceuticals, Inc. has showed a 74.62% decrease.
SLRX net income for the last quarter is −881.80 K USD, while the quarter before that showed −2.44 M USD of net income which accounts for 63.90% change. Track more Salarius Pharmaceuticals, Inc. financial stats to get the full picture.
Today Salarius Pharmaceuticals, Inc. has the market capitalization of 2.09 M, it has increased by 4.60% over the last week.
No, SLRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, SLRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Salarius Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 2.00 employees. See our rating of the largest employees — is Salarius Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Salarius Pharmaceuticals, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Salarius Pharmaceuticals, Inc. stock shows the sell signal. See more of Salarius Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Salarius Pharmaceuticals, Inc. future price: according to them, SLRX price has a max estimate of 3.25 USD and a min estimate of 3.25 USD. Read a more detailed Salarius Pharmaceuticals, Inc. forecast: see what analysts think of Salarius Pharmaceuticals, Inc. and suggest that you do with its stocks.